Answers are grounded in this paper and cite their sources.
Overall Response Rates Were Higher With Jaka at Week 24 Regardless of Organs Involved at Baseline vs BAT 3 § Patients included in the study were 12 years and older, had undergone allogeneic HSCT from any donor source/type, and had evident myeloid and platelet engraftment. 4II BATs included ibrutinib, extracorporeal photopheresis, low-dose methotrexate, mycophenolate mofetil, rituximab, everolimus, sirolimus, imatinib, in iximab, or pentostatin. 4¶ Steroid-refractory disease was de ned as lack of response or disease progression after ≥1 week of prednisone 1 mg/kg/day, disease persistence without improvement after ≥4 weeks of prednisone >0.5 mg/kg/day or 1 mg/kg every other day, or increase in prednisone dose to >0.25 mg/kg/day after 2 unsuccessful attempts to taper the dose. 3,5ACH3 was a randomized, open-label, multicenter, phase 3 study of Jaka vs BAT in patients with steroid-refractory cGVHD (N=329). 1,2§|| ¶ The starting dose for Jaka was 10 mg BID.Crossover from BAT to Jaka was permitted on or after Week 24 if patients progressed, had a mixed or unchanged response, developed toxicity to BAT, or experienced a cGVHD are. 1Intervene with Jaka in your appropriate patients with cGVHD.Learn more at hcp.Jaka .com52.
No takes yet. Share an insight, caveat, or question.
Benjamin Y. Kong (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: